Experimental human sepsis models

Tom Van Der Poll

doi:https://doi.org/10.1016/j.ddmod.2011.07.007

Experimental human sepsis models

Tom Van Der Poll

Research output: Contribution to journal › Review article › Academic › peer-review

5 Citations (Scopus)

Abstract

Human models that adequately mimic the clinical and pathological sequelae of sepsis are not available. Intravenous injection of lipopolysaccharide (a component of the gram-negative bacterial cell wall) into healthy humans has been used as a model with some relevance for sepsis, in particular to study mechanisms that may contribute to induction of pro- and anti-inflammatory pathways and to obtain proof of principle for the action of new anti-inflammatory compounds in a controlled setting in humans.

Original language	English
Pages (from-to)	e3-e9
Journal	Drug Discovery Today: Disease Models
Volume	9
Issue number	1
DOIs	https://doi.org/10.1016/j.ddmod.2011.07.007
Publication status	Published - 2012

Access to Document

https://doi.org/10.1016/j.ddmod.2011.07.007

Cite this

@article{b3a3a3dde6dc4a139453fdf9f7875079,

title = "Experimental human sepsis models",

abstract = "Human models that adequately mimic the clinical and pathological sequelae of sepsis are not available. Intravenous injection of lipopolysaccharide (a component of the gram-negative bacterial cell wall) into healthy humans has been used as a model with some relevance for sepsis, in particular to study mechanisms that may contribute to induction of pro- and anti-inflammatory pathways and to obtain proof of principle for the action of new anti-inflammatory compounds in a controlled setting in humans.",

author = "{Van Der Poll}, Tom",

year = "2012",

doi = "https://doi.org/10.1016/j.ddmod.2011.07.007",

language = "English",

volume = "9",

pages = "e3--e9",

journal = "Drug Discovery Today: Disease Models",

issn = "1740-6757",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - Experimental human sepsis models

AU - Van Der Poll, Tom

PY - 2012

Y1 - 2012

N2 - Human models that adequately mimic the clinical and pathological sequelae of sepsis are not available. Intravenous injection of lipopolysaccharide (a component of the gram-negative bacterial cell wall) into healthy humans has been used as a model with some relevance for sepsis, in particular to study mechanisms that may contribute to induction of pro- and anti-inflammatory pathways and to obtain proof of principle for the action of new anti-inflammatory compounds in a controlled setting in humans.

AB - Human models that adequately mimic the clinical and pathological sequelae of sepsis are not available. Intravenous injection of lipopolysaccharide (a component of the gram-negative bacterial cell wall) into healthy humans has been used as a model with some relevance for sepsis, in particular to study mechanisms that may contribute to induction of pro- and anti-inflammatory pathways and to obtain proof of principle for the action of new anti-inflammatory compounds in a controlled setting in humans.

UR - http://www.scopus.com/inward/record.url?scp=84862205531&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.ddmod.2011.07.007

DO - https://doi.org/10.1016/j.ddmod.2011.07.007

M3 - Review article

SN - 1740-6757

VL - 9

SP - e3-e9

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

IS - 1

ER -

Experimental human sepsis models

Abstract

Access to Document

Other files and links

Cite this